GlassScriptPhysician profile
Demis Khaimov
NPI 1538598693
$1,361.68
in general payments reported to CMS, 2019-2025
22 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $84.48 · 2023: $221 · 2024: $612 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $340.95 | 2023-2024 | Tepezza, Repatha |
| Corcept Therapeutics | $221.31 | 2021-2024 | Korlym |
| Chiesi USA, INC. | $134.31 | 2024-2025 | Mycapssa |
| Lilly USA, LLC | $108.66 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Boston Scientific Corporation | $70.75 | 2024-2025 | General - Kidney Stone Disease |
| Janssen Pharmaceuticals, INC | $53.95 | 2023 | Xarelto |
| Novo Nordisk INC | $45.67 | 2023-2025 | Wegovy |
| Mannkind Corporation | $43.36 | 2024 | |
| Amneal Pharmaceuticals LLC | $38.89 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $35.47 | 2024 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $28.23 | 2023 | Tymlos |
| Recordati_rare_diseases_inc. | $26.68 | 2025 | Isturisa |
| Civco Medical Instruments | $24.40 | 2025 | |
| Dexcom, INC. | $24.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.86 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.90 | 2021 | |
| Janssen Scientific Affairs, LLC | $22.13 | 2022 | |
| Esperion Therapeutics, INC. | $21.60 | 2025 | Nexletol |
| Vifor Pharma, INC. | $20.85 | 2021 | |
| Medtronic, INC. | $19.44 | 2024 | Minimed 780g |
| Urovant Sciences INC | $18.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demis Khaimov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.